VCN 01

Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VCN Biosciences
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer; Retinoblastoma

Most Recent Events

  • 03 Aug 2017 Phase-I clinical trials in Retinoblastoma (In infants, In children, Second-line therapy or greater, Late-stage disease) in Spain (Intravitreous) (EudraCT2016-001060-11)
  • 24 Jan 2017 Preclinical trials in Retinoblastoma in Spain (Intravitreous) before January 2017
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top